Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors

Journal of Virology

Volumn 86, Issue 4, 2012, Pages 2293-2301

  Khare, Reeti ^a   Reddy, Vijay S ^b   Nemerow, Glen R ^b   Barry, Michael A ^a,c  

^a MAYO CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 5 VECTOR; ADENOVIRUS VECTOR; CAPSID PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYSTEINE; HEXON PROTEIN; MACROGOL; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR SRA II; SCAVENGER RECEPTOR SREC; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; KUPFFER CELL; LIVER; MOLECULAR RECOGNITION; MOUSE; MUTATION; NONHUMAN; PEGYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CAPSID PROTEINS; CELL LINE; FEMALE; HUMANS; KUPFFER CELLS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, SCAVENGER;

ADENOVIRIDAE;

EID: 84857079734     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05760-11     Document Type: Article

References (37)

1. Alemany R, Suzuki K, Curiel DT. 2000. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81:2605-2609.
2. Ashkenas J, et al. 1993. Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors. J. Lipid Res. 34:983-1000.
3. Bergelson JM, et al. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
4. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV. 2004. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J. Biol. Chem. 279:51250-51257.
5. Bowdish DM, Gordon S. 2009. Conserved domains of the class A scavenger receptors: evolution and function. Immunol. Rev. 227:19-31.
6. Bristol JA, Shirley P, Idamakanti-N, Kaleko M, Connelly S. 2000. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol. Ther. 2:223-232.
7. Campos SK, Barry MA. 2007. Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7:189-204.
8. Croyle MA, Cheng X, Wilson JM. 2001. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8:1281-1290.
9. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 2001. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75:4792-4801.
10. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. 2009. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther. 20:975-988.
11. Espenlaub S, et al. 2010. Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. Hum. Gene Ther. 21:1155-1167.
12. Green NK, et al. 2004. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11:1256-1263.
13. Haisma HJ, et al. 2009. Scavenger receptor A: a new route for adenovirus 5. Mol. Pharm. 6:366-374.
14. Haisma HJ, et al. 2008. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J. Gen. Virol. 89:1097-1105.
15. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA. 2007. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther. 18:837-848.
16. Kalyuzhniy O, et al. 2008. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 105:5483-5488.
17. Khare R, Chen CY, Weaver EA, Barry MA. 2011. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr. Gene Ther. 11:241-258.
18. Khare R, et al. 2011. Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol. Ther. 19:1254-1262.
19. Kreppel F, Gackowski J, Schmidt E, Kochanek S. 2005. Combined genetic and chemical capsid modifications enable flexible and efficient deand retargeting of adenovirus vectors. Mol. Ther. 12:107-117.
20. Liu H, et al. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 329:1038-1043.
21. Liu Q, Muruve DA. 2003. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10:935-940.
22. McDonald D, Stockwin L, Matzow T, Blair Zajdel ME, Blair GE. 1999. Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumor cells. Gene Ther. 6:1512-1519.
23. Mizuta K, et al. 2009. Stability of the seven hexon hypervariable region sequences of adenovirus types 1-6 isolated in Yamagata, Japan between 1988 and 2007. Virus Res. 140:32-39.
24. Mok H, Palmer DJ, Ng P, Barry MA. 2005. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11:66-79.
25. Nicol CG, et al. 2004. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 10:344-354.
26. Parker AL, et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108:2554-2561.
27. Prill JM, et al. 2010. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol. Ther. 19:83-92.
28. Reddy VS, Natchiar SK, Stewart PL, Nemerow GR. 2010. Crystal structure of human adenovirus at 3.5 Å resolution. Science 329:1071-1075.
29. Rux JJ, Burnett RM. 2000. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1:18-30.
30. Shashkova EV, May SM, Barry MA. 2009. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology [Epub ahead of print].
31. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. 2005. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79:7478-7491.
32. Snoeys J, et al. 2007. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther. 14:604-612.
33. Waddington SN, et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
34. Weaver EA, et al. 2011. Characterization of species C human adenovirus serotype 6 (Ad6). Virology 412:19-27.
35. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. 1993. Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
36. Wu E, Nemerow GR. 2004. Virus yoga: the role of flexibility in virus host cell recognition. Trends Microbiol. 12:162-169.
37. Xu Z, Tian J, Smith JS, Byrnes AP. 2008. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82:11705-11713.